On the other hand, according to a Jan. 14 Associated Press story, Genentech’s 2007 profit of $2.77 billion was up 31% over 2006. And annual revenue was $11.72 billion, up 26 percent from a year earlier. Though Avastin sales have recently slowed, those are still huge figures.
Is there no middle ground here? Someplace where shareholders’ stock price and patients’ drug cost can comfortably co-exist?
Illness, death, and profit–strange bedfellows, indeed.
Like what you're reading? Get convenient updates from PJ Hamel on Facebook, iGoogle, your personal blog and more!
< Previous Post:
BRCA1: Startling New Findings Point to Need for Wider TestingPeople who read this also read...
What the community is saying...
Chemo Regimen FAQs: CAF or FAC Chemotherapy
Posted 07/17 Comments (1)
Q. My doctor tells me I have to have...
